Resonant Therapeutics utilizes a scalable tumor microenvironment platform to identify and validate highly selective tumor targets for antibody drug development. This approach accelerates the discovery of effective therapeutic goals, addressing the challenge of targeting specific tumor characteristics in cancer treatment.
Funding
$2.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The development of effective antibody drugs for cancer treatment is hindered by the difficulty of identifying highly selective tumor targets. Traditional methods often struggle to differentiate between tumor-specific characteristics and those of healthy tissues, leading to off-target effects and reduced efficacy. This lack of specificity poses a significant challenge in creating targeted therapies that can effectively combat cancer while minimizing harm to the patient.
Solution
Resonant Therapeutics has developed a scalable tumor microenvironment platform designed to identify and validate highly selective tumor targets for antibody drug development. This platform enables the discovery of novel targets that are specifically expressed or accessible within the tumor microenvironment, but not in normal tissues. By focusing on these unique tumor characteristics, Resonant Therapeutics aims to accelerate the development of antibody drugs with improved efficacy and reduced off-target effects. The platform's scalability allows for the efficient screening of a wide range of potential targets, increasing the likelihood of identifying promising candidates for therapeutic intervention.
Target Audience
The primary audience includes pharmaceutical companies and research institutions involved in the development of antibody drugs for cancer therapy.
Features
- Scalable tumor microenvironment platform for target discovery
- Identification of highly selective tumor targets
- Validation of targets for antibody drug development
- Focus on tumor-specific characteristics
- Accelerated discovery of effective therapeutic goals